• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Chembio Diagnostics Inc. (Amendment)

    2/9/22 3:33:37 PM ET
    $CEMI
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Get the next $CEMI alert in real time by email
    SC 13G/A 1 tv0568-chembiodiagnosticsinc.htm SCHEDULE 13G/A chembiodiagnosticsinc

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G

    Under the Securities Exchange Act of 1934
    (Amendment No.: 1)*

    Name of issuer:  Chembio Diagnostics Inc.

    Title of Class of Securities:  Common Stock

    CUSIP Number:  163572209

    Date of Event Which Requires Filing of this Statement: December 31, 2021

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☒ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

    (Continued on the following page(s))

     

     

    13G

    CUSIP No.:  163572209

    1.  NAME OF REPORTING PERSON
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

    The Vanguard Group - 23-1945930

    2.  CHECK THE APPROPRIATE [LINE] IF A MEMBER OF A GROUP

    A. 

    B.  X

    3.  SEC USE ONLY

    4.  CITIZENSHIP OF PLACE OF ORGANIZATION

    Pennsylvania

    (For questions 5-8, report the number of shares beneficially owned by each reporting person with:)

    5.  SOLE VOTING POWER

    0

    6.  SHARED VOTING POWER

    0

    7.  SOLE DISPOSITIVE POWER

    1,396,128

    8.  SHARED DISPOSITIVE POWER

    9,657

    9.  AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    1,405,785

    10.  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    N/A

    11.  PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    4.68%

    12.  TYPE OF REPORTING PERSON

    IA

     

     

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G
    Under the Securities Act of 1934

    Item 1(a) - Name of Issuer:

    Chembio Diagnostics Inc.

    Item 1(b) - Address of Issuer's Principal Executive Offices:

    555 Wireless Boulevard
    Hauppauge, NY 11788

    Item 2(a) - Name of Person Filing:

    The Vanguard Group - 23-1945930

    Item 2(b) – Address of Principal Business Office or, if none, residence:

    100 Vanguard Blvd.
    Malvern, PA 19355

    Item 2(c) – Citizenship:

    Pennsylvania

    Item 2(d) - Title of Class of Securities:

    Common Stock

    Item 2(e) - CUSIP Number

    163572209

    Item 3 - Type of Filing:

    This statement is being filed pursuant to Rule 13d-1.  An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E).

    Item 4 - Ownership:

      (a) Amount Beneficially Owned:

      (b) Percent of Class:

     

     

    (c)  Number of shares as to which such person has:

    (i)  sole power to vote or direct to vote:  

    (ii)  shared power to vote or direct to vote:  

    (iii)  sole power to dispose of or to direct the disposition of:  

    (iv)  shared power to dispose or to direct the disposition of:  

    Comments:

    The responses to questions 5 through 9 and 11 on the cover page(s) are incorporated by reference into this Item 4.  

    Item 5 - Ownership of Five Percent or Less of a Class:

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☒

    Item 6 - Ownership of More Than Five Percent on Behalf of Another Person:

    The Vanguard Group, Inc.'s clients, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities reported herein.

    No one other person's interest in the securities reported herein is more than 5%.

    Item 7 - Identification and Classification of the Subsidiary Which Acquired The Security Being Reported on by the Parent Holding Company:

    Not applicable

    Item 8 - Identification and Classification of Members of Group:

    Not applicable

    Item 9 - Notice of Dissolution of Group:

    Not applicable

    Item 10 - Certification:

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

    Signature

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date:  February 9, 2022

    By /s/ Christine M. Buchanan
    Name: Christine M. Buchanan
    Title:  Principal

    Get the next $CEMI alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CEMI

    DatePrice TargetRatingAnalyst
    7/22/2021Buy → Neutral
    Colliers Securities
    More analyst ratings

    $CEMI
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Biosynex Completes Acquisition of Chembio Diagnostics, Inc.

      Chembio Diagnostics, Inc. becomes the first North American structure controlled by Biosynex in North America STRASBOURG, France, April 27, 2023 (GLOBE NEWSWIRE) -- Biosynex SA ("Biosynex") (EPA: ALBIO), a French market leader specializing in the design and distribution of rapid tests, today announced it has completed its acquisition of Chembio Diagnostics, Inc. ("Chembio"), a leading point-of-care diagnostics company focused on infectious diseases. Chembio is now part of Biosynex Group. The complementary nature of the technologies and product portfolio as well as the combination of market opportunities will be important growth drivers for the combined company. In addition, significant ope

      4/27/23 4:30:00 PM ET
      $CEMI
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Chembio Stockholders Urged to Tender Shares Before 6:00 P.M., New York City Time, on April 26, 2023

      MEDFORD, N.Y., April 19, 2023 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (NASDAQ:CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today released the following letter to stockholders concerning the pending tender offer by Biosynex SA. April 19, 2023 Fellow Chembio Stockholders, We strongly urge you to tender your shares of common stock of Chembio Diagnostics Inc. ("Chembio") in the tender offer being made by Biosynex SA ("Biosynex") and its affiliates. The tender offer is the first step in a proposed merger between Chembio and Biosynex. Biosynex has agreed to pay $0.45 per share in cash to each of our stockholders who tender their shares prior t

      4/19/23 8:00:00 AM ET
      $CEMI
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Biosynex Extends Tender Offer for the shares of Chembio Diagnostics, Inc.

      STRASBOURG, France, April 13, 2023 (GLOBE NEWSWIRE) -- Biosynex SA ("Biosynex") (EPA: ALBIO), a French market leader specializing in the design and distribution of rapid tests, today announced that Project Merci Merger Sub, Inc. ("Purchaser"), a Nevada corporation and its wholly-owned indirect subsidiary, has extended the expiration time for the previously announced tender offer to purchase all of the issued and outstanding shares of common stock (the "Shares") of Chembio Diagnostics, Inc. (NASDAQ:CEMI) ("Chembio") at a price of $0.45 per Share, net to the seller in cash, without interest and subject to any required tax withholding, until 6:00 p.m., New York City time on April 26, 2023, un

      4/13/23 7:00:00 AM ET
      $CEMI
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $CEMI
    Financials

    Live finance-specific insights

    See more
    • Biosynex Completes Acquisition of Chembio Diagnostics, Inc.

      Chembio Diagnostics, Inc. becomes the first North American structure controlled by Biosynex in North America STRASBOURG, France, April 27, 2023 (GLOBE NEWSWIRE) -- Biosynex SA ("Biosynex") (EPA: ALBIO), a French market leader specializing in the design and distribution of rapid tests, today announced it has completed its acquisition of Chembio Diagnostics, Inc. ("Chembio"), a leading point-of-care diagnostics company focused on infectious diseases. Chembio is now part of Biosynex Group. The complementary nature of the technologies and product portfolio as well as the combination of market opportunities will be important growth drivers for the combined company. In addition, significant ope

      4/27/23 4:30:00 PM ET
      $CEMI
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Chembio Diagnostics Reports Third Quarter 2022 Financial Results

      HAUPPAUGE, N.Y., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. ("Chembio" or the "Company") (NASDAQ:CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today reported financial results for the quarter ended September 30, 2022. Recent Highlights Achieved third quarter 2022 total revenue of $11.2 million including product revenue of $10.8 million, representing product revenue growth of 16% compared to the prior year periodU.S. product revenue of $4.8 million grew 361% compared to the prior year periodAwarded $3.2 million contract from the CDC for development and clinical validation of Dual-Path Platform (DPP) Syphilis Treponemal Nontreponemal (

      11/3/22 4:05:00 PM ET
      $CEMI
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Chembio Diagnostics to Report Third Quarter 2022 Financial Results on November 3, 2022

      HAUPPAUGE, N.Y., Oct. 20, 2022 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (NASDAQ:CEMI), a leading point-of-care diagnostics company focused on infectious diseases, announced today that it will release financial results for the third quarter of 2022 after the close of trading on Thursday, November 3, 2022. The company's management team will host a corresponding conference call beginning at 4:30 p.m. Eastern Time on November 3, 2022. Investors interested in listening to the conference call may do so by dialing 888-506-0062 from the US or 973-528-0011 from outside the US and providing Entry Code: 600643 or by accessing www.chembio.com/investors/calendar-of-events/. A replay of the call

      10/20/22 4:05:00 PM ET
      $CEMI
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $CEMI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $CEMI
    SEC Filings

    See more

    $CEMI
    Leadership Updates

    Live Leadership Updates

    See more

    $CEMI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form 4 filed by Angelico Paul

      4 - CHEMBIO DIAGNOSTICS, INC. (0001092662) (Issuer)

      5/2/23 4:39:52 PM ET
      $CEMI
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form 4 filed by Acheson David

      4 - CHEMBIO DIAGNOSTICS, INC. (0001092662) (Issuer)

      5/1/23 9:03:38 PM ET
      $CEMI
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form 4 filed by Eberly Richard

      4 - CHEMBIO DIAGNOSTICS, INC. (0001092662) (Issuer)

      5/1/23 9:03:36 PM ET
      $CEMI
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form 15-12G filed by Chembio Diagnostics Inc.

      15-12G - CHEMBIO DIAGNOSTICS, INC. (0001092662) (Filer)

      5/8/23 9:26:46 PM ET
      $CEMI
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form EFFECT filed by Chembio Diagnostics Inc.

      EFFECT - CHEMBIO DIAGNOSTICS, INC. (0001092662) (Filer)

      5/3/23 12:15:15 AM ET
      $CEMI
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form EFFECT filed by Chembio Diagnostics Inc.

      EFFECT - CHEMBIO DIAGNOSTICS, INC. (0001092662) (Filer)

      5/3/23 12:15:13 AM ET
      $CEMI
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Chembio Diagnostics Announces Appointment of Larry Steenvoorden as Chief Financial Officer

      HAUPPAUGE, N.Y., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today announced the appointment of Larry Steenvoorden as Chief Financial Officer effective immediately. "We are thrilled to welcome Larry to the Chembio executive leadership team. Larry has developed valuable insights over his 25 years of financial leadership experience, spanning accounting, budgeting, public company reporting, business development, and commercial strategy. Those skills will be critical to our success as we scale our business in support of our corporate growth and operational objectives," said Richard Eber

      1/5/22 4:05:00 PM ET
      $CEMI
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Innovations in Disinfection Technology Aid the Return of Workers

      NEW YORK, Dec. 9, 2020 /PRNewswire/ -- The current pandemic has been devastating for the global economy and has caused severe backlogs in hospitals. Additionally, a spike in demand for Personal Protective Equipment (PPE) and new disinfecting technologies has also been seen. For example, when it comes for PPE, the global market was valued at USD 52.7 Billion in 2019 and is expected to reach USD 92.5 Billion by 2025 while growing at a CAGR of 8.7% during 2020-2025, according to VynZ Research. As for new technologies for disinfection, a recent example comes from LG Electronics, which announced on Wednesday the launch of a disinfection robot that will assist in containing the spread of the vi

      12/9/20 9:00:00 AM ET
      $NBY
      $CEMI
      $BSGM
      $DVAX
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
    • SEC Form SC 13D/A filed by Chembio Diagnostics Inc. (Amendment)

      SC 13D/A - CHEMBIO DIAGNOSTICS, INC. (0001092662) (Subject)

      5/4/23 6:07:59 AM ET
      $CEMI
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form SC 13D filed by Chembio Diagnostics Inc.

      SC 13D - CHEMBIO DIAGNOSTICS, INC. (0001092662) (Subject)

      5/1/23 9:21:54 AM ET
      $CEMI
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form SC 13D filed by Chembio Diagnostics Inc.

      SC 13D - CHEMBIO DIAGNOSTICS, INC. (0001092662) (Subject)

      4/7/23 5:19:51 PM ET
      $CEMI
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $CEMI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Chembio Diagnostics downgraded by Colliers Securities

      Colliers Securities downgraded Chembio Diagnostics from Buy to Neutral

      7/22/21 7:27:54 AM ET
      $CEMI
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Colliers Securities resumed coverage on Chembio Diagnostics with a new price target

      Colliers Securities resumed coverage of Chembio Diagnostics with a rating of Buy and set a new price target of $8.00

      3/11/21 4:06:26 AM ET
      $CEMI
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care